Axiall Corp (NYSE:AXLL) is screaming higher. Shares of the basic materials company's shares are up more than 10% thanks to an upgrade from Goldman Sachs. And according to analyst, Brian Maguire, there could be a lot more days like today.
Maguire tells investors that AXLL's earnings could double and rates Axiall as a "Buy," up from "Neutral," with a price-target of $60; another 29.7% upside as we type.
Axiall Corporation operates as an integrated chemicals and building products company in North America and Asia. Its products are used in various applications, including plastics, pulp and paper production, packaging, chemical intermediates, pharmaceuticals, medical and agricultural applications and paints, acrylics, and varnishes. The company was formerly known as Georgia Gulf Corporation and changed its name to Axiall Corporation in January 2013.
Top 10 Mid Cap Companies For 2015: Gen-Probe Incorporated(GPRO)
Gen-Probe Incorporated engages in the development, manufacture, and marketing of molecular diagnostic products and services that are used primarily to diagnose human diseases and screen donated human blood. Its women?s health product line includes APTIMA Combo 2 assay, APTIMA CT, APTIMA GC assays, and PACE family of assays to detect chlamydia and gonorrhea; APTIMA Trichomonas ASRs to detect trichomonas; APTIMA HPV assay to detect 14 sub-types of high-risk HPV associated with cervical cancer; and AccuProbe Group B Streptococcus (GBS) assay to detect GBS from culture. The company?s infectious diseases product line comprises ProFlu+ to detect influenza A, B, and Respiratory syncytial virus; ProFAST+ to detect and differentiate seasonal H1, seasonal H3, and H1N1pdm09; ProGastro Cd to detect toxigenic strains of clostridium difficile; AMPLIFIED MTD to detect mycobacterium tuberculosis; GAS Direct to detect gas directly from a throat swab; APTIMA HIV-1 and APTIMA HCV assays to detect RNA from HIV-1 and hepatitis C virus; and ASRs for quantitative HCV testing. Its blood screening products include Procleix HIV-1/HCV, Procleix Ultrio, Procleix Ultrio Plus, and Procleix WNV assays to detect HIV-1, HCV, HBV, and west nile virus in donated blood, plasma, organs, and tissues. The company?s transplant diagnostics products comprise LIFECODES HLA DNA typing kits; LIFECODES HLA antibody kits; LIFECODES PF4 assay to detect PF4 heparin-dependent antibodies; and LIFECODES PAK products for platelet antibody screening and detection. It also provides instrumentation and software for performing NAT assays; and genetic testing products, such as PROGENSA PCA3 and PCA3 ASRs to detect the PCA3 genes. The company serves reference laboratories, public health institutions, and hospitals through its direct sales force in United States, Canada, and Europe, as well as through distributors internationally. Gen-Probe Incorporated was founded in 1983 and is headquartered in S an Diego, California.
Advisors' Opinion:- [By Jayson Derrick]
Analysts at JMP Securities initiated coverage of GoPro (NASDAQ: GPRO) with a Market Outperform rating and $60 price target. Shares gained 13.0 percent, closing at $41.63.
- [By MONEYMORNING.COM]
Action-camera company GoPro Inc. (Nasdaq: GPRO) released more information about its upcoming IPO on Wednesday, saying the company plans to raise up to $427.2 million in the deal. That would give the company a valuation of approximately $3 billion.
- [By Keith Noonan]
GoPro (NASDAQ: GPRO ) continues to take investors on a wild ride. On Oct. 30, the company delivered quarterly earnings that were significantly better than expectations. The company's targets for the current fiscal quarter may have been even more promising. Compared to the analyst predictions of $503 million for the fourth quarter, the company expects between $550 million and $580 million in sales. The holiday sales stretch is crucial for GoPro, and signs of strength heading into the period bode well for the company's broader prospects.
- [By Monica Gerson]
Broker Recommendation
Analysts at JP Morgan downgraded GoPro (NASDAQ: GPRO) from Overweight to Neutral. The target price for GoPro is set to $51.
Top Building Product Companies To Own For 2014: Pacira Pharmaceuticals Inc.(PCRX)
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, commercialization, and manufacture of pharmaceutical products for use in hospitals and ambulatory surgery centers. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its product portfolio includes EXPAREL, a long-acting non-opioid postsurgical analgesic for postsurgical pain management; DepoCyt for the treatment of lymphomatous meningitis, a cancer of the immune system; DepoDur for controlling post operative pain; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis oncology. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By Jay Silverman]
So, first off Jay, congratulations. Among the 81 top picks in the 2013 report, The Medical Technology Stock Letter had the second best performing stock, Pacira Pharmaceuticals (PCRX), which was up 180%. Could you tell us a little about the company and the reasoning behind that original recommendation?
- [By John Udovich]
Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron�� where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs�Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech�IPO Setbacks. FierceBiotech has�summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia,�slashed its asking price on 6.9 million shares to $12 a share to raise $82 million�from a range of $16 to $19 a share while�Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer,�has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming�Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its�new, patient-friendly approach for delivering inhaled nitric oxide on the
Top Building Product Companies To Own For 2014: OpenTable Inc.(OPEN)
OpenTable, Inc. provides restaurant reservation solutions in the United States, Canada, Germany, Japan, Mexico, and the United Kingdom. It offers solutions that form an online network connecting reservation-taking restaurants and people who dine at those restaurants. The company provides electronic reservation book (ERB) that combines proprietary software and computer hardware to deliver a solution, whcih computerizes restaurant host-stand operations. The ERB streamlines and enhances various functions and processes for restaurants, including reservation management, table management, guest recognition, and email marketing. The company also operates opentable.com, a restaurant reservation Website that enables diners to find, choose, and book tables at restaurants on the OpenTable network in real time. In addition, it offers Connect, a Web-based service that enables restaurants to accept online reservations from the OpenTable network, as well as through its mobile application s and restaurants' Websites. Further, the company provides POP program, which lets restaurants offer diners bonus Dining Reward Points for reservations at select times; and telephone reservation management services for restaurants. Additionally, it operates toptable.com, a restaurant reservation site; designs, builds, and operates the OTRestaurant Website, which serves as an information and services portal for its restaurant customers; and offers versions of the OpenTable Websites for use on mobile devices, as well as free mobile applications. OpenTable, Inc. was founded in 1998 and is headquartered in San Francisco, California.
Advisors' Opinion:- [By Rex Crum]
OpenTable (OPEN) �shares surged 47% to $103.57 after it agreed to be acquired by online travel agency Priceline.com Inc. (PCLN) �for $2.6 billion in cash. The deal values OpenTable at $103 a share. Priceline�� shares fell 3% on the day.
- [By Matt Koppenheffer and David Hanson]
The bank is aiming to boost interaction through Facebook (NASDAQ: FB ) and OpenTable (NASDAQ: OPEN ) and allow consumers to�vote on favorite restaurants. Overall, the ultimate goal is make the customer base stickier.�
- [By Jeremy Bowman]
Elsewhere,�OpenTable� (NASDAQ: OPEN ) rocketed 48% higher after�priceline.com�snatched up the reservation specialist for $2.6 billion. Priceline shares fell 3% on the day, perhaps a reflection of the steep premium it paid. The acquisition gives the online travel leader an avenue in the restaurant industry, as airline and hotel reservations have become highly competitive, and provides it with ready-set relationships with more than 23,000 restaurants. OpenTable generates revenue by charging restaurants $1 every time a diner makes a reservation through its system. Priceline has risen to a valuation of more than $60 billion, in large part due to acquisitions of companies such as Kayak and Booking.com, so OpenTable should continue its strong growth under its auspices. The news also sent shares of Yelp�up 13% as investors speculated that the business-review site could be an attractive acquisition target, as well.
Top Building Product Companies To Own For 2014: Active Control Techn (ACTV)
The Active Network, Inc. provides organization-based cloud computing applications services to business customers in North America, Europe, and internationally. The company offers ActiveWorks, an organization-based cloud computing platform, which transforms the way organizers record, track, manage, and share information regarding activities and events. Its ActiveWorks back-office system pulls customers� participant management, operational reporting, volunteer management, and service and payment processing functions into one hosted system. The company also provides consulting services, which consist primarily of business mapping, project management services, and guidance on best practices in using its services; and implementation services, including system set-up and configuration, and data conversion, as well as develops customized training and education programs relating to both the use and administration of its services. It serves a range of customers, including communit y and sports organizations, large corporations, small and medium-sized businesses, educational institutions, federal and state government agencies, non-profit organizations, and other related entities. The company was formerly known as Racegate.com, Inc. and changed its name to The Active Network, Inc. in May 2001. The Active Network, Inc. was founded in 1998 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Luke Jacobi]
The Active Network (NYSE: ACTV) closed up 25.53 percent to $14.31 after the company agreed to be taken private by Vista Equity Partners for $1.05 billion.
- [By Selena Maranjian]
The biggest new holdings are Liberty Media�and AbbVie. Other new holdings of interest include The Active Network (NYSE: ACTV ) , which specializes in online registrations for endurance events such as marathons and triathlons. The company recently signed a three-year deal with Ironman, and its most recent quarterly earnings report featured revenue up 12% and shrinking losses. Some have questioned the company's solvency, while others like its valuation.
